The purpose of this review is to examine the contribution of the PI3K signaling pathway to the development of human tumors and to propose further studies to elucidate how to develop therapeutics for patients with mutations in this pathway.
Introduction
Phosphoinositide kinases (PIKs) are lipid kinases that phosphorylate the inositol ring of phosphoinositides, thus acting as signal transducers. Depending on the phosphorylation site on the carbohydrate, PIKs are categorized into three families: phosphoinositide 3-kinases (PI3Ks), phosphoinositide 4-kinases (PIP4Ks) and phosphoinositide 5-kinases (PIP5Ks). PI3Ks are further grouped into class I, II or III, depending on their subunit structure, their regulation and their substrate selectivity. Each class contains various isoforms amounting to eight isoforms in total.
Class I PI3Ks exist as heterodimers composed of catalytic and a regulatory subunits [1, 2] . When the PI3K complex is activated by growth factor receptor tyrosine kinases, the complex is recruited from the cytoplasm to the receptor on the inner cell membrane. There, PIK3CA phosphorylates its substrate phosphatidylinositol (4, 5) bisphosphate (PIP 2 ) at the 3-position of the inositol ring, forming the secondary messenger phosphatidylinositol (3, 4, 5) triphosphate (PIP 3 ). PIP 3 levels are tightly regulated by the action of phosphatases such as the phosphatase and tensin homolog (PTEN) [3] [4] [5] and SH2-containing inositol 5-phosphatase (SHIP) [6] . PIP 3 serves as an anchor for Pleckstrin Homology (PH) domain-containing proteins such as the serine/threonine kinases AKT1, AKT2 and AKT3, which, once localized to the membrane, get activated by 3-phosphoinositide dependent protein kinase-1 (PDK1). AKT has numerous protein targets, including mTor, Bad, Caspase 9, Tuberin, GSK3b and a subset of forkhead transcription factors. The biological consequences of AKT activation are broad and can be subdivided into regulation of cell proliferation, survival and motility [1, 2, 7] . Several PI3K isoforms have been implicated in human diseases. PI3Ka, which belongs to the class IA of PI3Ks and whose catalytic domain is encoded by PIK3CA, is mutated in a significant fraction of tumor types [8] [9] [10] [11] . More importantly, several of these mutations have been shown to have oncogenic potential [8, [12] [13] [14] .
Primary links between the PI3K pathway and cancer
The PI3K pathway has been shown to be linked to cancer development for at least a decade. Chang and colleagues [15] reported that the ASV16 genome encodes an oncogene that is derived from the PI3K gene, and that this gene, like its cellular counterpart, is potently transforming. In addition, the murine lymphoma virus AKT8 was shown to carry the cell-derived viral oncogene, AKT, which produces thymic lymphomas in mice [16] . Both these findings are strong indications that stringent regulation of the PI3K pathway is required to avoid oncogenesis.
Deciphering the various components of the PI3K pathway has allowed functional correlations to be determined between the pathway and cancer development. For example, overexpression of the AKT gene has been shown to be transforming [17] . In addition, PTEN, which dephosphorylates the lipid product of PI3Ks, thus antagonizing PI3K activity, acts as a tumor suppressor. Heterozygous PTEN knockout mice and mice with mutant PTEN show increased tumor development [18] [19] [20] .
The strongest and most reliable evidence for gene involvement in cancer development is derived from genetic analysis. A well known genetic alteration of this pathway is the loss of the tumor suppressor PTEN, which occurs in several different tumor types [4, 5, 21, 22] and results in constitutive activation of the PI3K pathway. Other well known genetic alterations in this pathway include the amplification of genomic regions containing AKT or PIK3CA genes [23] [24] [25] [26] [27] [28] [29] and mutations in the regulatory subunit of PI3K, p85, in ovarian and colon tumors [30] . Furthermore, the fact that the downstream targets of AKT, FKHR and FKHRL1 have been shown to be translocated in several tumor types [31] provides strong evidence that this pathway plays a major role in neoplasia.
Further genetic deregulation of the PI3K pathway
The studies noted above stimulated us to determine whether PI3K genes were genetically altered in human tumors. Sequencing of the exons encoding the kinase domain of all 16 members of the PI3K family showed that PIK3CA was the only gene to harbor somatic (i.e. tumorspecific) mutations. Sequencing the rest of the gene revealed that PIK3CA is somatically mutated in 32% of colorectal cancers [8] . This discovery led to the examination of PIK3CA mutations in additional cancer types, showing it to be mutated in 27% of glioblastomas [8, 32] , 25% of gastric cancers [8, 33] , 36% of hepatocellular carcinomas [34] , 18-40% of breast cancers [9, 11, [35] [36] [37] , 4-12% of ovarian cancers [36, 38] and 4% of lung cancers [8] . From these mutation frequencies, PIK3CA is one of the two most commonly mutated genes identified in human cancers (the other being KRAS).
If two genes are mutated in a mutually exclusive fashion in a single tumor type, it is likely that they provide the same selective pressure for clonal expansion. This concept has been demonstrated by the mutual exclusivity found between APC and beta catenin mutations [39, 40] or Ras and B-raf mutations [41, 42] . An indication that this notion is also true for the PI3K pathway comes from the work of Saal et al. [35] . In this study, the PIK3CA mutation status of a panel of breast tumors which had lost PTEN expression was compared with a matched control set that had retained PTEN expression. A highly significant association between PIK3CA mutations and retention of wild-type PTEN protein expression was observed.
Another genetic study aimed at testing the involvement of additional members of the PI3K pathway in CRC oncogenesis evaluated 146 CRCs for somatic mutations in this pathway. Somatic mutations were identified in PDK1 (3/146), p21-activated kinase 4 (PAK4) (2/146), AKT2 (2/146), insulin-related receptor INSRR (1/146), v-Erb-B erythroblastic leukemia viral oncogene homolog ERBB4 (1/146), PTEN (7/146), as well as amplification of the insulin receptor substrate IRS2 (3/146). When these same tumors were analyzed for PIK3CA mutations, 37 mutations were found [43] . Thus, a total of 58 alterations were found in the PI3K pathway, and only two of the tumors had alterations of two genes in the PI3K pathway, making this mutual exclusivity statistically significant (P ¼ 0.02, chi-square test). This suggests that activation of the PI3K pathway can be achieved by mutation at various levels in the pathway.
Functional deregulation of the PI3K pathway
Functional evidence showing that dysregulation of the PI3K pathway is involved in tumorigenesis has been provided by various studies: abrogation of PTEN activity results in increased growth signals and promotion of tumor formation [18] [19] [20] 44, 45] and the PI3K p110 subunit as well as AKT has been shown to be transforming [17, 46, 47] . In addition, transfection of cells with constitutively active AKT inhibits apoptosis induction while expression of dominant negative AKT blocks the ability of growth factors to promote survival [48] .
Several genetic indications suggest mutant PIK3CA is an oncogene: the high mutation frequency of PIK3CA; nearly all of the alterations found to date have been heterozygous missense changes; and many of the mutations affect highly conserved residues.
In addition, more than 80% of the mutations in PIK3CA cluster in two regions, within the helical and catalytic domains. The presence of hotspot alterations suggests that these changes may be kinase activating, similar to oncogenic mutations found in genes such as K-RAS and B-RAF [41, 42, 49] . In fact, examination of the lipid kinase activity of recombinant PIK3CA mutants in vitro as well as overexpression studies of mutant PIK3CA in mammalian cells and chicken embryo fibroblast cells (CEFs) have shown that both hotspot mutations enhance the lipid kinase activity of PIK3CA [12] [13] [14] . Functional evidence indicating that mutant PIK3CA behaves as an oncogene is described below.
Biochemical analysis of cells harboring mutant PIK3CA
Recent studies showed that overexpression of PIK3CA mutants in CEFs as well as in NIH3T3 cells induced the phosphorylation of AKT and oncogenic transformation compared with wild-type PIK3CA [12, 14] . Another study provided functional evidence that mutant PIK3CA is an oncogene by using two colorectal cell lines harboring each of the hotspot mutations (E545K and H1047R) that expressed either the wild-type or the mutant PIK3CA allele (Fig. 1) [13] . Biochemical analysis of these cells showed that both hotspot mutations increased the phosphorylation of AKT dramatically. These data demonstrate increased PI3K signaling in the mutant clones compared with the wild-type clones.
As mentioned above, AKT is known to have numerous substrates [1, 2] . The above clones were used to determine which of these are the major targets in CRCs containing PIK3CA mutations. Surprisingly, mutant PIK3CA clones had highly phosphorylated FKHRL1 and FKHR compared with wild-type clones, while other major AKT downstream targets, such as mTor, 4EBP1, Tuberin and GSK3b, showed no alteration in their phosphorylation status. As three human AKT genes -AKT1, AKT2 and AKT3 -are known and all have similar structural features [48, 50] , isoform-specific antibodies were used to determine which AKT isoform is activated by mutant PIK3CA. A clear increase in phosphorylation of AKT1, but not AKT2 or AKT3, was observed [13] . This correlates well with a recent study which evaluated AKT1, AKT2 and AKT3 expression in epithelial cells. AKT1 but not AKT2 was found to be essential for survival and AKT3 was not expressed in CRCs [51] . Thus, mutant PIK3CA appears to modulate specifically the phosphorylation events of AKT1, FKHR and FKHRL1 in CRCs; this is summarized schematically in Figure 2 . These results differ from the ones observed in the study by Kang et al. [12] and Ikenoue et al. [14] , in which overexpression of mutant PIK3CA in CEFs or NIH3T3 cells affected the phosphorylation status of additional members of the AKT pathway such as mTor targets. Thus, AKT downstream targets may differ in a cell and organism-specific manner.
Growth analysis of cells harboring mutant PIK3CA
When the aforementioned cells containing either the wild-type or the mutant PIK3CA alleles were examined for alterations in growth phenotypes, no differences were found when the cells were grown in 10% serum. When serum concentrations were reduced to suboptimal levels (0.5% serum), however, the cells containing wild-type PIK3CA grew at a significantly lower rate than the cells containing either the helical or the kinase domain mutation. The underlying mechanism for this phenotypic difference was found to be that reduced serum concentrations induced apoptosis in cells containing wild-type PIK3CA but not in clones containing the mutant allele.
The above biochemical and growth results are consistent with data demonstrating that mice deficient in AKT1 are susceptible to serum withdrawal-induced apoptosis [52] , and that AKT1 is essential for cell survival [51] . Importantly, AKT1 is also one of the major downstream effectors of PTEN. As mentioned above, deletion of the murine PTEN gene leads to increased tumor development [18] [19] [20] . Deletion of AKT1 in PTEN(À/À) embryonic stem cells partially reverses the aggressive growth of PTEN(À/À) cells in vivo [53] , suggesting that AKT1 plays an essential role both in PTEN and PIK3CA-controlled tumorigenesis. These studies emphasize that activation of AKT1 is involved in resistance to apoptosis and that it triggers this phenotype in cells containing either mutant PIK3CA or mutant PTEN. 
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As mentioned above, PIK3CA activation and PTEN disruption cause the accumulation of PIP 3 and activate similar signal transduction pathways. Some insight into the oncogenic activity of mutant PIK3CA can therefore be derived from studies analyzing the tumor suppressor activity of PTEN. An important phenotype that has been observed from such studies is that PTEN inhibits cell migration, spreading and focal adhesion formation [54, 55] . Accordingly, cell clones containing mutant PIK3CA as opposed to wild-type PIK3CA showed an increase in cell migration and invasion ability [13] . Strikingly, when wildtype and mutant clones were administered to athymic nude mice by tail vein injection, none of the mice injected with the wild-type clones had tumors, while all the mice that received mutant clones had tumors in various locations. When microscopic examination was performed on the mice, no additional tumors were found in the mice injected with wild-type clones and numerous tumor micrometastases and evidence of tumor invasion was observed in mice receiving mutant clones [13] . These results are consistent with functional analysis showing that AKT regulates migration and invasion [56] [57] [58] [59] . For example, Kim et al. [56] found AKT to be localized to the membrane of the leading edge of migrating cancer cells. This localization was shown to be dependent on the lipid binding ability of the Pleckstrin Homology binding domain of AKT. As mentioned above, AKT1 was the main AKT isoform observed to be activated downstream of mutant PIK3CA [13] . This jives with the fact that immunohistochemical examination of activated AKT found that AKT1 but not AKT2 or AKT3 was active in thyroid cancers and that immunoactive pAkt was greatest in regions of capsular invasion [58] .
These data also are consistent with the fact that PIK3CA mutations occur at the point when benign colorectal tumor cells acquire the ability to invade (i.e. the adenoma to carcinoma transition) [8] . It can therefore be suggested that oncogenic PIK3CA plays a role in inducing invasion in naturally occurring tumors. As cancer is defined as a state wherein tumor cells invade surrounding tissues, PIK3CA can specifically be classified as a cancer gene rather than a tumor gene. Given that invasion and metastasis are responsible for most cancer mortality, knowledge about oncogenic PIK3CA activity is essential to understand these processes. A summary of the phenotypes induced by oncogenic PIK3CA in CRCs is given in Table 1 . 
Conclusion: the view ahead
In order to gain further knowledge about the oncogenic PIK3CA pathway, we need to know what downstream proteins it activates and inhibits. It has already been shown that there is a selective involvement of FKHR and FKHRL1 in CRCs [13] and that in CEFs, overexpression of mutant PIK3CA increases the phosphorylation of S6K and 4EBP1 [12] . Upcoming work will determine whether these differences are due to the different experimental systems, species or cell types used. AKT1 was found to be the predominant AKT isoform found to be activated downstream of mutant PIK3CA in CRCs [13] . Further work will be required to determine AKT isoform specificity downstream of mutant PIK3CA in other cancer types. As AKT2 has been found to be amplified in breast, ovarian and pancreatic cancers [24] [25] [26] and mutated in CRCs [43] , it will be interesting to see whether a selective involvement of FKHR and FKHRL1 is also found in these cases.
It is as yet unclear what happens downstream of FKHR and FKHRL1 phosphorylation in CRC cells with PIK3CA mutations. It is known that phosphorylation of the transcription factors FKHR and FKHRL1, however, prevents the transcription of pro-apoptotic genes such as FasL and Bim [60] . Use of the clones depicted in Figure 1 in a microarray or SAGE analysis will help identify the genes that are exclusively upregulated or downregulated in cells with mutant PIK3CA compared with wild-type PIK3CA. These genes are likely to be involved in inducing the phenotypes described above. Agents that inhibit mutant enzymatic activities in cancer are, in principle, more selective and less toxic to normal cells. The best examples of this are provided by Gleevec, Iressa and Herceptin. It has been shown that mutational activation of PIK3CA is essential for tumor growth [13] and that mutant forms of PIK3CA are inhibited by the broadly acting PI3K inhibitor, LY294002 [13] . As LY294002 is known to be toxic in vivo, however, nontoxic small molecule inhibitors that target one or both of the two major mutant forms of PIK3CA (i.e. those in the kinase and helical domains) should be developed to treat patients whose tumors contain these mutations [61] . Another potential therapeutic target is AKT1, which is specifically activated by mutant PIK3CA [13] and mutant PTEN [53] .
Unraveling which proteins are activated as a result of mutations in PIK3CA should provide potential future diagnostic and therapeutic targets. Evaluation of tumors with genetic alterations in other components of the PI3K pathway (such as PTEN or AKT) and their comparison with tumors with mutation in PIK3CA will allow us to find common denominators that should further illuminate pathogenesis. The PIK3CA gene was targeted in DLD1 and HCT116 cell lines. HCT116 cells contain a PIK3CA kinase domain mutation while DLD1 cells contain a helical domain mutation. Clones in which the mutant allele has been disrupted and the wild-type allele is intact are referred to as wild-type clones, while clones in which the wild-type allele has been disrupted and mutant allele is intact are referred to as mutant clones. 'þ' indicates a low ability to perform the phenotype stated on the left, whereas 'þþþ' indicates a high ability to carry out that same phenotype.
